References
- Lee CA. Kawasaki disease. J Insur Med 2003;35:125-7.
- Lee DW, Kim YH, Hyun MC, Kwon TC, Lee SB. NT-proBNP as a useful tool in diagnosing incomplete Kawasaki disease. Korean J Pediatr 2010;53:519-24. https://doi.org/10.3345/kjp.2010.53.4.519
- Lee H, Kim H, Kim HS, Sohn S. NT-pro BNP: a new diagnostic screening tool for Kawasaki disease. Korean J Pediatr 2006;49:539-44. https://doi.org/10.3345/kjp.2006.49.5.539
- Bang S, Yu JJ, Han MK, Ko HK, Chun S, Choi HS, et al. Logtransformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction. Korean J Pediatr 2011;54:340-4. https://doi.org/10.3345/kjp.2011.54.8.340
- Kaneko K, Yoshimura K, Ohashi A, Kimata T, Shimo T, Tsuji S. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol 2011;32:1106-9. https://doi.org/10.1007/s00246-011-9986-8
- Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005;11(5 Suppl):S76-80. https://doi.org/10.1016/j.cardfail.2005.04.009
- Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
- McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 2007;116:174-9. https://doi.org/10.1161/CIRCULATIONAHA.107.690875
- Mir TS, Laux R, Hellwege HH, Liedke B, Heinze C, von Buelow H, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003;112:896-9. https://doi.org/10.1542/peds.112.4.896
- Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003;49:1563-4. https://doi.org/10.1373/49.9.1563
- Hammerer-Lercher A, Mair J, Tews G, Puschendorf B, Sommer R. N-terminal pro-B-type natriuretic peptide concentrations are markedly higher in the umbilical cord blood of newborns than in their mothers. Clin Chem 2005;51:913-5. https://doi.org/10.1373/clinchem.2004.046557
- Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in kawasaki disease. Korean Circ J 2011;41:379-84. https://doi.org/10.4070/kcj.2011.41.7.379
Cited by
- Diagnosing Incomplete Kawasaki Disease vol.6, pp.3, 2016, https://doi.org/10.4103/sjmms.sjmms_166_17
- Dengue-Triggered Kawasaki Disease : A Report of 2 Cases vol.24, pp.7, 2018, https://doi.org/10.1097/rhu.0000000000000704
- N-terminal probrain natriuretic peptide as biomarker for diagnosis of Kawasaki disease vol.13, pp.4, 2016, https://doi.org/10.2217/bmm-2018-0324
- Cardiovascular Involvement in Kawasaki Disease Is Much More Than Mere Coronary Arteritis vol.8, pp.None, 2016, https://doi.org/10.3389/fped.2020.526969
- N-terminal pro-B-type natriuretic peptide levels in children: comparison in cardiac and non-cardiac diseases vol.30, pp.4, 2020, https://doi.org/10.1017/s1047951120000402
- Predictive value of heart rate deceleration capacity on coronary artery lesion in acute phase of Kawasaki disease vol.10, pp.None, 2020, https://doi.org/10.1038/s41598-020-67121-3